On display

Molecular reagents that bind to specific proteins with high affinity are valuable tools in the endeavour to understand protein function. In the Early Edition of Proceedings of the National Academy of Science, Wilson et al. describe how a method based on mRNA display can be used to identify ligands with higher affinity than those selected using the phage display technique. The new technique generates polypeptides that are linked via a puromycin moiety to their encoding mRNAs. Wilson et al. demons

By | March 20, 2001

Molecular reagents that bind to specific proteins with high affinity are valuable tools in the endeavour to understand protein function. In the Early Edition of Proceedings of the National Academy of Science, Wilson et al. describe how a method based on mRNA display can be used to identify ligands with higher affinity than those selected using the phage display technique. The new technique generates polypeptides that are linked via a puromycin moiety to their encoding mRNAs. Wilson et al. demonstrate that the limitations of non-constrained linear peptide libraries can be overcome by increasing the complexity (the diversity) of the library and the length of the polypeptides. Using an ultra-high complexity library of 1013 random peptides, each 88 amino acids long, they selected 20 different aptamers which bound to a protein target with dissociation constants as low as 5 nM. Such an approach therefore has advantages over antibody production or phage display techniques to screen for high-affinity protein-binding reagents.

Popular Now

  1. How Plants Evolved Different Ways to Make Caffeine
  2. Thomson Reuters Predicts Nobelists
    The Nutshell Thomson Reuters Predicts Nobelists

    According to citation statistics, researchers behind programmed cell death pathways and CRISPR/Cas9 are among those in line for Nobel Prizes this year.

  3. Sequencing Reveals Genomic Diversity of the Human Brain
  4. Reviewing Results-Free Manuscripts
    The Nutshell Reviewing Results-Free Manuscripts

    An open-access journal is trialing a peer-review process in which reviewers do not have access to the results or discussion sections of submitted papers.

RayBiotech